Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer 1

Interventions

pembrolizumab 409 Cyclophosphamide 398 Carboplatin 307 Gemcitabine 286 Nivolumab 276 Paclitaxel 274 Cisplatin 252 Radiotherapy 225 Dexamethasone 209 Bevacizumab 207 fludarabine 195 Docetaxel 186 Rituximab 183 Capecitabine 171 Oxaliplatin 158 Lenalidomide 157 Fluorouracil 152 Temozolomide 138 Cytarabine 135 Etoposide 128 Irinotecan 124 Cetuximab 123 fludarabine phosphate 121 Injections 118 venetoclax 116 Ipilimumab 115 Doxorubicin 114 Azacitidine 108 130-nm albumin-bound paclitaxel 108 Pemetrexed 107

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Interventional × tildrakizumab × Clear all

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡